The coevolution of IDO1 and AhR in the emergence of regulatory T-cells in mammals

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Grohmann, Ursula ^a,b   Puccetti, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aryl hydrocarbon receptor; Immune regulation; Indoleamine 2,3 dioxygenase 1 and 2; Tryptophan dioxygenase; Tryptophan metabolism

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; INDOLEAMINE 2, 3 DIOXYGENASE; MICRORNA; TRYPTOPHAN; UNCLASSIFIED DRUG;

COEVOLUTION; CONVERGENT EVOLUTION; EDITORIAL; GENETIC TRANSCRIPTION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LACTOBACILLUS; MAMMAL; MICROBIOME; NONHUMAN; REGULATORY T LYMPHOCYTE; TRYPTOPHAN METABOLISM; TUMOR ESCAPE;

EID: 84926632405     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00058     Document Type: Editorial

References (32)

1. Bessede A, Gargaro M, Pallotta MT, Matino D, Macchiarulo A, Vacca C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 511:184-90. doi: 10.1038/nature13323
2. Moura-Alves P, Fae K, Houthuys E, Dorhoi A, Kreuchwig A, Furkert J, et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature (2014) 512:387-92. doi:10.1038/nature13684
3. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Fallarino F, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 39:372-85. doi:10.1016/j.immuni.2013.08.003
4. Di Meglio P, Duarte JH, Ahlfors H, Owens ND, Li Y, Villanova F, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity (2014) 40:989-1001. doi:10.1016/j.immuni.2014.04.019
5. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 24:242-8. doi:10.1016/S1471-4906(03)00072-3
6. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 4:762-74. doi:10.1038/nri1457
7. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol (2007) 7:817-23. doi:10.1038/nri2163
8. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC, et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol (2006) 177:130-7. doi:10.4049/jimmunol.177.1.130
9. Fallarino F, Grohmann U, Vacca C, Orabona C, Bianchi R, Belladonna ML, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 176:6752-61. doi:10.4049/jimmunol.176.11.6752
10. Fallarino F, Grohmann U, Orabona C, Bianchi R, Belladonna ML, Puccetti P, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 4:1206-12. doi:10.1038/ni1003
11. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Puccetti P, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ (2002) 9:1069-77. doi:10.1038/sj.cdd.4401073
12. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 22:633-42. doi:10.1016/j.immuni.2005.03.013
13. Austin CJ, Rendina LM. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today (2014). doi:10.1016/j.drudis.2014.11.007
14. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 12:870-8. doi:10.1038/ni.2077
15. Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 18:834-42. doi:10.2119/molmed.2012.00029
16. Pallotta MT, Orabona C, Bianchi R, Vacca C, Fallarino F, Belladonna ML, et al. Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes. J Cell Mol Med (2014) 18(10):2082-91. doi:10.1111/jcmm.12360
17. Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol (2009) 41:467-71. doi:10.1016/j.biocel.2008.01.005
18. Gobert M, Lafaille JJ. Maternal-fetal immune tolerance, block by block. Cell (2012) 150:7-9. doi:10.1016/j.cell.2012.06.020
19. Williams Z. Inducing tolerance to pregnancy. N Engl J Med (2012) 367:1159-61. doi:10.1056/NEJMcibr1207279
20. Ball HJ, Jusof FF, Bakmiwewa SM, Hunt NH, Yuasa HJ. Tryptophan catabolizing enzymes-party of three. Front Immunol (2014) 5:485. doi:10.3389/fimmu.2014.00485
21. Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in immunomodulation and autoimmune disease. Front Immunol (2014) 5:585. doi:10.3389/fimmu.2014.00585
22. Zelante T, Iannitti RG, Fallarino F, Gargaro M, De Luca A, Moretti S, et al. Tryptophan feeding of the IDO1-AhR axis in host-microbial symbiosis. Front Immunol (2014) 5:640. doi:10.3389/fimmu.2014.00640
23. Schmidt SV, Schultze JL. New insights into IDO biology in bacterial and viral infections. Front Immunol (2014) 5:384. doi:10.3389/fimmu.2014.00384
24. Nguyen NT, Nakahama T, Le DH, Van Son L, Chu HH, Kishimoto T. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol (2014) 5:551. doi:10.3389/fimmu.2014.00551
25. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet (2011) 12:846-60. doi:10.1038/nrg3079
26. Nakahama T, Hanieh H, Nguyen NT, Chinen I, Ripley B, Millrine D, et al. Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad Sci U S A (2013) 110:11964-9. doi:10.1073/pnas.1311087110
27. Pallotta MT, Fallarino F, Matino D, Macchiarulo A, Orabona C. AhR-mediated, non-genomic modulation of IDO1 function. Front Immunol (2014) 5:497. doi:10.3389/fimmu.2014.00497
28. Jaronen M, Quintana FJ. Immunological relevance of the coevolution of IDO1 and AHR. Front Immunol (2014) 5:521. doi:10.3389/fimmu.2014.00521
29. Julliard W, Fechner JH, Mezrich JD. The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front Immunol (2014) 5:458. doi:10.3389/fimmu.2014.00458
30. Holtzhausen A, Zhao F, Evans KS, Hanks BA. Early carcinogenesis involves the establishment of immune privilege via intrinsic and extrinsic regulation of indoleamine 2,3-dioxygenase-1: translational implications in cancer immunotherapy. Front Immunol (2014) 5:438. doi:10.3389/fimmu.2014.00438
31. Platten M, von Knebel-Döberitz N, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol (2015) 5:673. doi:10.3389/fimmu.2014.00673
32. van Baren N, Van den Eynde B. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol (2015) 6:34. doi:10.3389/fimmu.2015.00034